Synonyms: BMY-13805 | BMY13805 | Exxua® | MJ-13805 | MJ13805 | ORG-13011 | Travivo (gepirone extended-release)
gepirone is an approved drug (FDA (2023))
Compound class:
Synthetic organic
Comment: Gepirone (BMY-13805) is a 5-HT1A receptor agonist [5].
|
|
Bioactivity Comments |
The extended release formulation of gepirone has a short elimination half-life of ~6 hours [6]. Like buspirone it is converted to a pyrimidinepiperazin metabolite that acts as a potent α2-adrenoceptor antagonist [1]. Gepirone displaces [3H]8-OH-DPAT from human 5-HT1A receptors with a Ki of 13 nM [2]. |